The Global Health Body Issues Alert Over Acute Scarcity of Weight-Loss Jabs

Less than 10% of patients who could benefit from weight-loss injections like Wegovy can access them, caution the WHO as it issues its first recommendations on the drugs.

With in excess of 1,000,000,000 individuals worldwide now classified as obese, it is calling for increased and just availability to these injectable treatments.

According to forecasts, more than two billion are projected to be obese by 2030 without intervention.

"Our new guidelines affirms that obesity is a chronic disease that can be managed with thorough and lifelong treatment," stated WHO director-general Tedros Adhanom Ghebreyesus.

Substantial prices, insufficient output, and distribution challenges are key barriers to universal access to the injections that can assist patients in reducing considerable weight, explains the body.

Weight-Loss Drug Scarcity

Even under the current best projected case, the production of these medications would only suffice for approximately 100 million people – fewer than 10% of eligible patients, according to the WHO.

The recommendation encourages nations and manufacturers to widen access, via strategies including voluntary licensing.

A patent on semaglutide – the core component of a leading brand – is due to expire in a number of nations in 2026.

The Way Obesity Injections Operate

The injections replicate a biological compound to reduce digestion speed, curb appetite and increase feelings of fullness so people consume fewer calories.

Individuals typically start to lose weight in the initial weeks of starting on the weekly injections.

Studies points to patients may put most of the weight back on after a year of halting the medication, because their usual food cravings come back.

Being carrying excess weight increases your chance for contracting diseases, like type 2 diabetes, heart disease, stroke, and specific malignancies.

Obesity concerns individuals in all nations and was responsible for millions of fatalities worldwide in 2024, as per the health agency.